Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Systematic Review Article

Systematic Review of Local Studies Regarding Efficiency of Add-On Medications on Negative Symptoms of Schizophrenia: A Meta-Analysis

Author(s): Saeed Shoja Shafti*

Volume 8 , Issue 2 , 2019

Page: [113 - 122] Pages: 10

DOI: 10.2174/2211556008666190405143828

Abstract

Background: While negative symptoms are connected with poor functioning and quality of life, pharmacological managements have imperfect effects on deficit syndrome and may even subsidize or aggravate secondary negative symptoms. Meanwhile, management of negative symptoms by means of add-on medications has resulted in instable consequences.

Objective: In the current tryout, some of the indigenous systematic issued studies have been the theme of a new meta-analysis, to assess the effectiveness of adjunctive psychotropic drugs on deficit syndrome of schizophrenia.

Methods: Twelve randomized placebo-control trials (n=433), which had been implemented in Razi psychiatric hospital in the last 14 years, had been selected for the present analysis. As a shared protocol, all cases had been selected amongst the male inpatients, who were hospitalized in chronic section of the hospice and had been diagnosed schizophrenia in line with “Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision”. In this regard, the aforesaid samples had been entered into matching-group, double-blind assessments for random assignment to a psychotropic medication (like antidepressant, benzodiazepine, psycho-stimulant, Acetyl-cholinesterase inhibitors) or placebo in addition to their current drug. In these trials, “Scale for Assessment of Negative Symptoms (SANS)” had been used as the main outcome measure for evaluation of negative symptoms. Also, response was defined as a decrease in ≥20% in the severity of SANS score (over-all and/or sub-scales).

Results: While the heterogeneity of the present meta-analysis was intermediate, the “Combined Effect Size” of the aforesaid assessments has revealed a significant influence respecting efficiency of psychotropic drugs on negative symptoms of schizophrenia (OR = 5.40, CI=2.69- 10.85, z= 5.32, p<0.000). Similar results, as well, could be found in connection with various negative symptoms. In this regard, ‘Anhedonia-Asociality’ showed the best “Combined Effect Size”, afterwards “Affective Blunting”, “Avolitio -Apathy”, “Attention Deficit”, and last of all “Alogia”. “Heterogeneity” of all said analysis was insignificant and therefore appropriate.

Conclusion: According to the findings, psychotropic drugs, as add-on medications, have valuable influence in regard to amelioration of negative symptoms of schizophrenia.

Keywords: Antidepressants, benzodiazepine, cholinesterase inhibitor, deficit syndrome, negative symptoms, schizophrenia, stimulants.

Graphical Abstract
[1]
Blanchard JJ, Kring AM, Horan WP, et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull 2011; 37(2): 291-9.
[2]
Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia. commentary. Schizophr Bull 2006; 32: 246-9.
[3]
Andreasen N. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39: 784-8.
[4]
Tarrier N. Negative symptoms in schizophrenia: comments from a clinical psychology perspective. Schizophr Bull 2006; 32: 231-3.
[5]
Remington G, Foussias G, Fervaha G, et al. Treating negative symptoms in schizophrenia: an update. Curr Treat Options Psychiatry 2016; 3: 133-50.
[6]
Shoja Shafti S. Odyssey of ‘negative symptoms’ of schizophrenia: rehabilitation vs. stigmatization. Curr Psychopharmacol 2015; 4(1): 1-12.
[7]
Potvin S, Elie R, Sepehry AA. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007; 68(4): 604-10.
[8]
Möller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003; 17(11): 793-823.
[9]
Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions. Clin Psychol Rev 2013; 33(8): 914-28.
[10]
Knegtering R, Aleman A, Lange JJ. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry 2010; 71(4): 411-8.
[11]
Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 2004; 5(10): 2053-8.
[12]
Bauer A, Godemann F, Reischies FM, et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2005; 20(1): 27-31.
[13]
Kissling W, Rummel C. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006; 19(3)CD005581
[14]
Stahl SM, Buckley PF. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 2007; 115(2): 93-100.
[15]
Shoja Shafti S. Meta-analysis of native studies as regards the effectiveness of antidepressants on deficit syndrome of schizophrenia: a systematic review. Curr Psychopharmacol 2017; 6(2): 1-10.
[16]
Shoja Shafti S. Effectiveness of citalopram, alprazolam and clomipramine in amelioration of negative symptoms in schizophrenia. Arch Rehab 2003; 3(12): 42-9.
[17]
Shoja Shafti S. Effectiveness of bromocriptine, fluoxetine and nortriptyline in ameliorating the negative symptoms of schizophrenia. Arch Rehab 2004; 5(16): 58-63.
[18]
Shoja Shafti S. Drug-specific responsiveness of negative symptoms. Psychiatr Rehabil J 2005; 10(1): 177-86.
[19]
Shoja Shafti S. Rehabilitation of schizophrenia: adjunctive therapy of negative symptoms. Iran Rehabil J 2004; 1(2): 22-31.
[20]
Shoja Shafti S. Amelioration of negative symptoms in schizophrenia by escitalopram: a double blind, placebo-controlled clinical trial. Clin Schizophrenia Related Psychosis 2007; 1: 255-8.
[21]
Shoja Shafti S. Treatment-responsiveness of negative symptoms in schizophrenia: a double-blind placebo-control clinical trial. Iran J Med Sci 2006; 31: 135-8.
[22]
Shoja Shafti S, Jafarabad MS, Azizi R. Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor. Ther Adv Psychopharmacol 2015; 5(5): 1-8.
[23]
Shoja Shafti S, Azizi Khoei A. Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Ther Adv Psychopharmacol 2016; 6(5): 308-16.
[24]
Shoja Shafti S, Akbari S. Intractability of deficit syndrome of schizophrenia against adjunctive modafinil. J Clin Psychopharmacol 2016; 36(1): 1-5.
[25]
Spitzer R. Diagnostic and statistical manual of men-tal disorders. 4th ed. American Psychiatric Associa-tion: Washington, DC 2000.
[26]
Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989; 7: 49-58.
[27]
Andreasen N. The scale for assessment of positive symptoms (SAPS). Br J Psychiatry Suppl 1989; 7: 49-58.
[28]
Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212(44): 11-9.
[29]
Hamilton M. Rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56.
[30]
Folstein MF, Folstien SE, McHugh PR. Mini- mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189.
[31]
Kring AM, Germans-Gard M, Gard DE. Emotion deficits in schizophrenia: timing matters. J Abnorm Psycho 2011; 120: 79.
[32]
Tamminga CA. Schizophrenia and other psychotic disorders: Introduction and overview. In: Sadock BJ, Sadock VA, Ruiz P, Eds. Comprehensive Textbook of Psychiatry. 9th ed. Lippincott Williams & Wilkins: Philadelphia 2009.
[33]
Czobor P, Möller HJ. Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2015; 265(7): 567-78.

© 2022 Bentham Science Publishers | Privacy Policy